Clinical Trial

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Study acronym: PROACT 2
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13
notable Primary completion pushed: 2026-05-15 -> 2027-06-01 2026-05-09
minor Completion pushed: 2027-05-01 -> 2027-06-01 2026-05-09
Trial Details
NCT Number NCT05850091
Lead Sponsor Massachusetts General Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Coronary Artery Disease
Enrollment 200 participants
Start Date 2023-12-07
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12